Asthma

Researchers agree the telemedicine is empowering physicians to more efficiently and conveniently handle patients, and is expected to provide increasingly demonstrable positive therapeutic benefits

Mepolizumab reduced Asthma Control Questionnaire scores from baseline by –1.45 in patients that had uncontrolled asthma with omalizumab.

KIT inhibition with imatinib reduced mast cells in patients with severe asthma in a proof-of-concept trial, but is the treatment feasible for the future?

Jonathan Spergel, MD, PhD, and his team linked eosinophilic esophagitis to the condition-based theory. What others are part of the atopic march?

While multi-faceted approaches have been shown to be cost-effective, realistically they can be costly and impractical to implement. But environmental and educational interventions hold some promise.

The president of the American College of Allergy, Asthma & Immunology talked the session's future impact, upcoming therapies, and what his favorite lectures were.

African Americans have a 2.5-fold greater chance for developing asthma and a 1.8-fold greater chance for developing eczema, but ironically have a lower chance of receiving a FA diagnosis compared to white children.

Despite being the traditional practice, increasing inhaled controller therapy doses during yellow-zone episodes does not stop asthma exacerbations.

While peanut butter exposure aids children from an early age, fish oil could improve asthma rates.

While the data have been met with conflicting opinions, environmental interventions for allergens in the home hold potential for asthma.

The researcher from Ghent University in Belgium discussed the improved quality of life patient with severe nasal polyps experience with monoclonal antibodies.

Policy interventions and medication are the best available methods for improving the negative impact pollutants have on patients.

Improving asthma management in schools not only benefits pediatric patients' health, but improves attendance rates.

Early allergen sensitization is associated with an increased risk of viral infections and the development of childhood asthma.

The FDA previously approved DUPIXENT in the US for the treatment of adults with moderate-to-severe atopic dermatitis.

The medication has also been linked to increased risk of autism and reduced IQ.